Brolucizumab
Modify Date: 2025-09-08 11:55:28
Brolucizumab structure
|
Common Name | Brolucizumab | ||
|---|---|---|---|---|
| CAS Number | 1531589-13-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BrolucizumabBrolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer[1][2]. |
| Name | Brolucizumab |
|---|
| Description | Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Brolucizumab (2683 nM) 抑制 VEGF-A112 诱导的 U87MG 人神经胶质瘤细胞中的 VEGFR1 磷酸化和 ZHE-483-2 GMEC 中的 VEGFR2 磷酸化[1]。 |
| In Vivo | Brolucizumab (15 mg/kg; i.p. 5 days per week for 21 or 41 days) 可减缓 mSLK-KSHV 异种移植肿瘤的生长[2]。 Brolucizumab (5-50 mg/kg; i.p. once or twice daily for 28 days) 在 U87MG 神经胶质瘤模型中延迟体内肿瘤生长[1]。 Brolucizumab (10 mg/kg; i.v.) 在小鼠中显示出快速衰退期的半衰期为 5.4-7.8 分钟，缓慢衰退期的半衰期为 1.4-1.9 小时[2]。 Animal Model: NSG mice were subcutaneously injected with mSLK-KSHV cell suspension[2] Dosage: 15 mg/kg Administration: I.p. 5 days per week for 21 or 41 days Result: Significantly lowed tumor growth there was no difference in survival between experimental and combined control groups. |
| References |
| No Any Chemical & Physical Properties |